Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment

Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. – 2023 Consolidated Financial Statements
Attachment

Related Press Releases
 
                                                                      Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
 
                                                                      Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
 
                                                                      Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
 
                                                                      Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
 
                                                                      Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
 
                                                                      Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
 
                                                                      Ipsen announces changes to its Executive Committee
 
                                                                      Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
 
                                                                      Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
 
                                                                      Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary...